產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-C12ORF29抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-C12ORF29抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-C12ORF29
Cat. Number:
Anti-C12ORF29抗體KL-9946R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Encoding over 1,100 genes within 132 million bases, chromosome 12 makes up about 4.5% of the human genome. A number of skeletal deformities are linked to chromosome 12 including hypochondrogenesis, Anti-C12ORF29抗體achondrogenesis and Kniest dysplasia. Noonan syndrome, which includes heart and facial developmental defects among the primary symptoms, is caused by a mutant form of PTPN11 gene product, SH-PTP2. Chromosome 12 is also home to a homeobox gene cluster which encodes crucial transcription factors for morphogenesis, and the natural killer complex gene cluster encoding C-type lectin proteins which mediate the NK cell response to MHC I interaction. Trisomy 12p leads to facial development defects, seizure disorders and a host of other symptoms varying in severity depending on the extent of mosaicism and is most severe in cases of complete trisomy. The C12orf29 gene product has been provisionally designated C12orf29 pending further characterization.
Also known as:
CL029_HUMAN; Anti-C12ORF29抗體Uncharacterized protein C12orf29.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human C12ORF29.
●
Predicted Molecular Weight: 37kDa.
Storage:
Shipped at 4℃, Anti-C12ORF29抗體Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200
Not yet tested in other applications.
Optimal working Anti-C12ORF29抗體dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working Anti-C12ORF29抗體dilutions must be determined by the end user.
kl073Hu02 白介素12受體β2(IL2Rβ2)多克隆抗體 Polyclonal Antibody to Interleukin 12 Receptor Beta 2 (IL12Rb2)
kl006Mu02 雙調(diào)蛋白(AREG)多克隆抗體 Polyclonal Antibody to Amphiregulin (AREG)
kl009Mu02 血管生成素2(ANGPT2)多克隆抗體 Polyclonal Antibody to Angiopoietin 2 (ANGPT2)
kl010Mu02 結(jié)締組織生長(zhǎng)因子(CTGF)多克隆抗體 Polyclonal Antibody to Connective Tissue Growth Factor (CTGF)
kl011Mu02 腦源性神經(jīng)營(yíng)養(yǎng)因子(BDNF)多克隆抗體 Polyclonal Antibody to Brain Derived Neurotrophic Factor (BDNF)
kl012Mu02 S100鈣結(jié)合蛋白(S100)多克隆抗體 Polyclonal Antibody to S100 Calcium Binding Protein (S100)
kl013Bo01 骨成型蛋白2(BMP2)多克隆抗體 Polyclonal Antibody to Bone Morphogenetic Protein 2 (BMP2)
kl013Mu02 骨成型蛋白2(BMP2)多克隆抗體 Polyclonal Antibody to Bone Morphogenetic Protein 2 (BMP2)
kl014Mu02 骨成型蛋白4(BMP4)多克隆抗體 Polyclonal Antibody to Bone Morphogenetic Protein 4 (BMP4)
kl015Bo01 骨成型蛋白受體1A(BMPR1A)多克隆抗體 Polyclonal Antibody to Bone Morphogenetic Protein Receptor 1A (BMPR1A)
kl015Mu02 骨成型蛋白受體1A(BMPR1A)多克隆抗體 Polyclonal Antibody to Bone Morphogenetic Protein Receptor 1A (BMPR1A)
kl019Mu02 白介素8受體α(IL8Rα)多克隆抗體 Polyclonal Antibody to Interleukin 8 Receptor Alpha (IL8Ra)
kl020Mu01 唾液酸結(jié)合Ig樣凝集素3(SIGLEC3)多克隆抗體 Polyclonal Antibody to Sialic Acid Binding Ig Like Lectin 3 (SIGLEC3)
kl020Mu02 唾液酸結(jié)合Ig樣凝集素3(SIGLEC3)多克隆抗體 Polyclonal Antibody to Sialic Acid Binding Ig Like Lectin 3 (SIGLEC3)
kl021Mu02 睫狀神經(jīng)營(yíng)養(yǎng)因子(CNTF)多克隆抗體 Polyclonal Antibody to Ciliary Neurotrophic Factor (CNTF)
kl022Mu02 血管內(nèi)皮細(xì)胞蛋白C受體(PROCR)多克隆抗體 Polyclonal Antibody to Protein C Receptor, Endothelial (PROCR)
kl024Mu02 ***腺來(lái)源血管內(nèi)皮生長(zhǎng)因子(EG-VEGF)多克隆抗體 Polyclonal Antibody to Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)
